 |
Viking Therapeutics’ weight loss oral drug showed effectiveness in early-stage studies.
Viking recently announced their weight loss oral drug VK2735 effectively reduced weight in a small-scale, early-stage study.
Viking reported an average weight loss of 3.3% in just 28 days in seven subjects who took the maximum 40mg dosage of VK2735.
In addition, Viking stated they plan to conduct further studies with larger doses on more patients due to the drug’s mild side effects. The mid-stage study is expected to be conducted on obese patients by the end of this year.
Meanwhile, in a study on the VK2735 injectable, participants experienced an average weight loss of 15%.
Most Commented